2026-09-20T04:59:05Zhttps://dspace.mit.edu/server/oai/requestoai:dspace.mit.edu:1721.1/1228452026-06-16T18:14:05Zcom_1721.1_7582com_1721.1_7581col_1721.1_131022
Robert Langer.
Abramson, Alex Gilbert.
Massachusetts Institute of Technology. Department of Chemical Engineering.
Massachusetts Institute of Technology. Department of Chemical Engineering
2019-11-12T17:38:13Z
2019-11-12T17:38:13Z
2019
2019
https://hdl.handle.net/1721.1/122845
1126279165
Thesis: Ph. D., Massachusetts Institute of Technology, Department of Chemical Engineering, 2019
Cataloged from PDF version of thesis.
Includes bibliographical references (pages 189-201).
Macromolecule drugs such as insulin have transformed our capacity to effectively treat diseases; however, their rapid degradation and poor absorption in the gastrointestinal (GI) tract generally limits their administration to parenteral routes. An oral biologic delivery system must aid in both localization and permeation to achieve systemic drug uptake. In this thesis I will describe two oral capsules designed to systemically deliver macromolecules by inserting the drugs directly into the walls of the gastrointestinal tract. One device is designed to deliver to the stomach wall, while the other device is designed to deliver to the wall of the small intestine. Ex vivo studies on human GI tissue and in vivo studies in rats and swine support the devices' safety and high delivery efficiency. I perform a cost effectiveness analysis using a first and second order Monte Carlo simulation to show that these new methods of oral macromolecule delivery should increase the quality-adjusted life expectancies of patients suffering from diabetes. Moreover, I demonstrate that electronic systems can be incorporated into these devices for communication and additional therapeutic applications. With the ability to load a multitude of drug formulations, the devices can serve as platform technologies to orally deliver therapeutic doses of macromolecule drugs.
"NSF for providing me with a fellowship towards pursuing my graduate degree, and I want to acknowledge a grant from the National Institutes of Health for funding part of the research as well (EB-000244)"
by Alex Gilbert Abramson.
Ph.D.
Ph.D. Massachusetts Institute of Technology, Department of Chemical Engineering
201 pages
eng
Massachusetts Institute of Technology
MIT theses are protected by copyright. They may be viewed, downloaded, or printed from this source but further reproduction or distribution in any format is prohibited without written permission.
http://dspace.mit.edu/handle/1721.1/7582
Chemical Engineering.
Ingestible capsules for therapeutic injections in the gastrointestinal tract
Thesis
application/pdf
2019-11-12T17:38:12Z
Publication
Doctoral
ChemEng
unknown
unknown
<Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="ea19103a-0196-43dc-b062-c8211e03b9b6">
<Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843</Type>
<Language>eng</Language>
<Title>Ingestible capsules for therapeutic injections in the gastrointestinal tract</Title>
<PublishedIn>
<Publication>
</Publication>
</PublishedIn>
<PublicationDate>2019</PublicationDate>
<Authors>
<Author>
<DisplayName>Abramson, Alex Gilbert.</DisplayName>
<Affiliation>
<OrgUnit>
</OrgUnit>
</Affiliation>
</Author>
</Authors>
<Editors>
</Editors>
<Publishers>
<Publisher>
<DisplayName>Massachusetts Institute of Technology</DisplayName>
<OrgUnit />
</Publisher>
</Publishers>
<License>http://dspace.mit.edu/handle/1721.1/7582</License>
<Keyword>Chemical Engineering.</Keyword>
<Abstract>Macromolecule drugs such as insulin have transformed our capacity to effectively treat diseases; however, their rapid degradation and poor absorption in the gastrointestinal (GI) tract generally limits their administration to parenteral routes. An oral biologic delivery system must aid in both localization and permeation to achieve systemic drug uptake. In this thesis I will describe two oral capsules designed to systemically deliver macromolecules by inserting the drugs directly into the walls of the gastrointestinal tract. One device is designed to deliver to the stomach wall, while the other device is designed to deliver to the wall of the small intestine. Ex vivo studies on human GI tissue and in vivo studies in rats and swine support the devices' safety and high delivery efficiency. I perform a cost effectiveness analysis using a first and second order Monte Carlo simulation to show that these new methods of oral macromolecule delivery should increase the quality-adjusted life expectancies of patients suffering from diabetes. Moreover, I demonstrate that electronic systems can be incorporated into these devices for communication and additional therapeutic applications. With the ability to load a multitude of drug formulations, the devices can serve as platform technologies to orally deliver therapeutic doses of macromolecule drugs.</Abstract>
<Access xmlns="http://purl.org/coar/access_right"
>
</Access>
</Publication>